Klein I, Trzepacz P T, Roberts M, Levey G S
Department of Medicine, North Shore University Hospital, Manhasset, NY 11030.
Arch Intern Med. 1988 Feb;148(2):387-90.
A hyperthyroid symptom scale (HSS) was designed and administered to ten subjects with untreated Graves' disease. All subjects had clinical and chemical evidence of hyperthyroidism and reproducible HSS scores of 20 or more points. During sequential treatments with propranolol hydrochloride (phase 2) followed by propylthiouracil (phase 3) there was a significant decline in the HSS scores at each phase. Accompanying the decrease in HSS scores was a decrease in heart rate, but there was no change in thyroid function test results at phase 2 and a decrease in heart rate, thyroid function test results, and goiter size at phase 3. This new scale includes ten categories of symptoms, it is sensitive to changes in both the adrenergic and metabolic components of hyperthyroidism, and it is useful in the clinical assessment and management of patients with thyrotoxicosis.
设计了一种甲状腺功能亢进症状量表（HSS），并应用于10例未经治疗的格雷夫斯病患者。所有受试者均有甲状腺功能亢进的临床和化学证据，且HSS评分可重复达到20分或更高。在依次使用盐酸普萘洛尔治疗（第2阶段），随后使用丙硫氧嘧啶治疗（第3阶段）期间，每个阶段的HSS评分均显著下降。随着HSS评分的降低，心率也下降，但在第2阶段甲状腺功能测试结果无变化，在第3阶段心率、甲状腺功能测试结果和甲状腺肿大小均下降。这种新量表包括10类症状，它对甲状腺功能亢进的肾上腺素能和代谢成分的变化均敏感，并且在甲状腺毒症患者的临床评估和管理中有用。
